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introduction 
 
INTRODUCTION 1 
1.1. Analytical chemistry 
    Pharmaceutical Analysis may be defined as the application of analytical procedures 
used to determine the purity, safety and quality of drugs and chemicals. The term 
“Pharmaceutical analysis” is otherwise called quantitative pharmaceutical chemistry. 
Pharmaceutical analysis includes both qualitative and quantitative analysis of drugs and 
pharmaceutical substances starts from bulk drugs to the finished dosage forms. In the modern 
practice of medicine, the analytical methods are used in the analysis of chemical constituents 
found in human body whose altered concentrations during disease states serve as diagnostic 
aids and also used to analyze the medical agents and their metabolites found in biological 
system. 
The term “quality” as applied to a drug product has been defined as the sum of all 
factors, which contribute directly or indirectly to the safety, effectiveness and reliability of 
the product. These properties are built into drug products through research and during process 
by procedures collectively referred to as “quality control”. 
Quality control guarantees within reasonable limits that a drug products 
Is free of impurities. 
Is physically and chemically stable 
Contains the amount of active ingredients as stated on the label and 
Provides optimal release of active ingredients when the product is administered. 
 
 Types of analytical methods 
                                 Analytical methods can be separated into classical and instrumental.                                                                                               
classical methods (also known as wet chemistry methods) use separations such as 
precipitation, extraction, and distillation and qualitative analysis by color, odor, or melting 
point. Quantitative analysis is achieved by measurement of weighed or volume.  
                                   Instrumental methods use an apparatus to measure physical quantities 
of the analyte such as light absorption, fluorescence, or conductivity. The separation of 
materials is accomplished using chromatography or electrophoresis methods. 
Classification 
Classical methods 
Titration Reaction types 
1.Acid-Base Titrations 
                  Types of acid-base titrations.  
                   i Strong Acid / Strong Base: pH at equivalence point = 7. 
                   ii Weak Acid / Strong Base: pH at equivalence point >7. 
                   iii Strong Acid / Weak Base: pH at equivalence point <7. 
2.  Redox titrations. 
3. Complexometric Titrations. 
4. Zeta- potential Tittrations. 
5. Miscellaneous titration. 
6. Iodimetry titration. 
7. Precipitation titration. 
8. KjeldahlTitration.  
9. Argentometric Titrations. 
                  9.1 The Mohr titration. 
                  9.2 Volhard titration. 
                  9.3  Fajans titration. 
10. Classification of titration by end-point techniques. 
                  10.1 Conductometric titration. 
                  10.2 Potentiometric titration. 
                  10.3 Spectrophotometric titration 
                  10.4 Amperometric titration 
                  10.5 Thermometric or enthalpimetric titration. 
                  10.6 Nonaqueous titration. 
                  10.7 Automatic titration. 
                  10.8 electrochemical titration. 
11.  Back titrations 
Titrimetry types 
1. Volumetric titrimetry 
2. Gravimetric or weighed titrimetry 
                  i. Weighed drug after extraction. 
                  ii. Weighed a derivative after separation. 
                 iii. Weighed residue after ignition. 
3. Coulometric titrimetry. 
4. Standardization. 
                              
INSTRUMENTAL METHODS 
1. Spectrophotometric Methods. 
                   i. Dye complex methods. 
                   ii. Colourimetric method. 
                  iii. Ultra violet method. 
                  iv. Flourimetric method. 
                  v. Flame photometry. 
                  vi. Atomic absorption spectroscopy. 
                 vii. Infrared spectrophotometry. 
                 viii. Raman spectroscopy. 
                 ix. X-ray spectroscopy. 
                 x. Mass Spectroscopy. 
2. Electro analytical methods. 
                 i. Potentiometry. 
                 ii. Voltametry. 
                 iii. Coulometry. 
                 iv.Electrogravimetry. 
                 v. Conductance techniques. 
3. Chromatographic methods. 
                 i. Thin layer chromatography. 
                 ii. Paper chromatography. 
                 iii. Column chromatography. 
                 iv.Gas chromatography. 
                 v. High Performance Liquid Chromatography and high performance thin layer 
chromatography. 
4. Miscellaneous methods. 
                 i. Thermal analysis. 
                 ii. Kinetic techniques. 
                 iii. Enzyme assay. 
5. Hyphenated techniques. 
                 i. GC-MS (Gas chromatography – Mass spectrometry). 
                 ii. LC-MS (Liquid chromatography – Mass spectrometry). 
                 iii. GC-IR (Gas chromatography – Infrared spectroscopy). 
                 iv. ICP-MS (Inductively coupled plasma – Mass spectrometry). 
 
CHROMATOGRAPHY INTRODUCTION2 
Chromatography is the name applied to a group of analytical techniques for isolation 
of components in mixture for qualitative identification, purification and quantitative 
estimation of many components. 
Recently IUPAC has defined the chromatography as “A method used primarily for 
separation of the components of a mixture sample in which the components are separated and 
distributed between stationary phase and mobile phase. The stationary phase may be solid or 
liquid supported on a solid or gel and maybe packed in a column separated as a layer or 
distributed as a film, the mobile phase maybe gaseous or liquid.” 
The importance of Chromatography is increasing rapidly in pharmaceutical analysis. 
The exact differentiation, selective identification and quantitative determination of 
structurally closely related compounds are possible with chromatography. Another important 
field of application of chromatographic methods is the purity testing of final products and 
intermediates (detection of decomposition products and by products). As a consequence of 
the above points, chromatographic methods are occupying an ever-expanding position in the 
latest editions of the pharmacopoeias and other testing standards. 
The modern form of column chromatography has been called high performance, high 
pressure, high resolution and high speed liquid chromatography. 
High-Performance Liquid Chromatography (HPLC) is a special branch of column 
chromatography in which the mobile phase is forced through the column at high speed.  As a 
result the analysis time is reduced by 1-2 orders of magnitude relative to classical column 
chromatography and the use of much smaller particles of the adsorbent or support becomes 
possible increasing the column efficiency substantially.   
High performance liquid chromatography is the fastest growing analytical technique 
for the analysis of drugs.  Its simplicity, high specificity and wide range of sensitivity made it 
ideal for the analysis of many drugs in both dosage forms and biological fluids.  This 
technique is based on the same methods of separation as that of classical column 
chromatography i.e. adsorption, partition, ion exchange and gel permeation, but it differs 
from the column chromatography in the fact that the mobile phase is passed through the 
packed column under high pressure.  In classical open column chromatography, the mobile 
phase flows slowly through the column by means of gravity with the diameter of particles (of 
solid support) in the range of 150 - 200µm.  But in HPLC, the separation is about 100 times 
faster than the conventional liquid chromatography due to packing of particles in the range of 
3-10µm. Thus HPLC is having advantages of improved resolution, faster separation, 
improved accuracy, precision and sensitivity.  
              
 
 
 
    
 
 
 
 
 
 
 
 
1.2.HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 3 
      The term ‘Chromatography’ covers those processes aimed at the separation of the various   
species of a mixture on the basis of their distribution characteristics between a stationary and 
a mobile phase.  
Instrumentation of HPLC 
                               
.                      
Principle of separation in HPLC  
The principle of separation in normal phase mode and reverse phase mode is adsorption. 
When a mixture of components is introduced in to a column, they travel according to their 
relative affinities towards stationary phase. The component which has more affinity towards 
the adsorbent travels slower. The component which has less affinity towards stationary phase 
travels faster. Since no two components have the same affinity towards the stationary phase, 
the components are separated HPLC is an analytical technique for resolution of solutes, in 
which separation is made by differential migration in a porous medium and migration is 
caused by flow of solvent. 
Chromatography is one of the widely used physiochemical methods of separation of 
inorganic and organic substances related in their composition and properties. 
Chromatography is characterized by two important features, 
                                         a. A very large interface area, and 
                                        b. A dynamic way of operation, which ensures a more effective 
separation of substances as compared to other methods. 
Modes of Chromatography 
        Modes of chromatography are defined essentially according to the nature of the 
interactions between the solute and the stationary phase, which may arise from hydrogen 
bonding, Vander walls forces, electrostatic forces or hydrophobic forces or basing on the size 
of the particles (e.g. Size exclusion chromatography). 
Advantages of HPLC 
- It is efficient, highly selective and widely applicable. 
- Only small sample amount is required for analysis. 
- Ordinarily nondestructive to sample. 
- HPLC readily adaptable to Quantitative analysis. 
- It is simple and inexpensive equipment compared to GC. 
- HPLC can accommodate nonvolatile and thermally unstable samples. 
- It is generally applicable to inorganic ions.  
Types of HPLC 
Based on the mode of separation 
Normal phase chromatography 
Reverse phase chromatography. 
Partition chromatography. 
Displacement chromatography. 
Based on principle of separation 
Adsorption chromatography. 
Ion exchange chromatography. 
Size exclusion chromatography. 
Affinity chromatography. 
Chiral phase chromatography. 
Ion pair chromatography. 
Based on elution technique 
Isocratic separation. 
Gradient separation. 
Based on the scale of operation 
Analytical HPLC. 
Preparative HPLC. 
Based on the type of analysis 
Qualitative analysis. 
Quantitative analysis. 
Based on the mode of separation 
 Normal Phase Chromatography 
                                          In normal phase chromatography, the stationary phase is a polar 
adsorbent and the mobile phase is generally a mixture of non-aqueous solvents. 
The silica structure is saturated with silanol groups at the end. These OH groups are 
statistically disturbed over the whole of the surface. The silanol groups represent the active 
sites (very polar) in the stationary phase. This forms a weak type of bond with any molecule 
in the vicinity when any of the following interactions are present. 
 Dipole-induced dipole 
 Dipole-dipole 
               Hydrogen bonding 
  π-Complex bonding 
These situations arise when the molecule has one or several atoms with lone pair electron or a 
double bond. The absorption strengths and hence k’ values (elution series) increase in the 
following order- Saturated hydrocarbons < olefins < aromatics < organic halogen compounds 
< sulphides < ethers< esters < aldehydes and ketones < amines < sulphones < amides < 
carboxylic acids. The strength of interactions depends not only on the functional groups in 
the sample molecule but also on steric factors. If a molecule has several functional groups, 
then the most polar one determines the reaction properties. 
      Chemically modified silica, such as the aminopropyl, cyanopropyl and diol phases are 
useful alternatives to silica gel as stationary phase in normal phase chromatography. 
      The aminopropyl and cyanopropyl phases provide opportunities for specific interactions 
between the analyte and the stationary phases and thus offer additional options for the 
optimizations of separations. Other advantages of bonded phases lie in their increased 
homogeneity of the phase surface. 
      Resolution with water in weak mobile phase may be most conveniently achieved by 
drying the solvents and then adding a constant concentration of water or some very polar 
modifier such as acetic acid or triethylamine (TEA) to the mobile phase. The addition of such 
polar modifiers serves to deactivate the more polar shape as well as the reproducibility of the 
retention times. 
Reversed Phase Chromatography 
                                                 Since 1960’s chromatographers started modifying the 
polar nature of silanol group is chemically reacting silica with organic silanes. The objective 
is to made less polar or non polar so that polar solvents can be used to separate water-soluble 
polar compounds. Since the ionic nature of the chemically modified silica is now reversed i.e. 
it is non-polar or the nature of the phase is reversed. The chromatographic separation carried 
out with such silica is referred to as reversed- phase chromatography. 
      A large number of chemically bonded stationary phases based on silica are available 
commercially. Silica based stationary phases are still most popular in reversed phase 
chromatography however other absorbents based on polymer (styrene-di-vinyl benzene 
copolymer) are slowly gaining ground. 
      The retention time decreases in the following order: aliphatics > induced dipoles (i.e. 
CCl4) > permanent dipoles (e.g.CHCl3) > weak Lewis bases (ethers, aldehydes, ketones) > 
strong Lewis bases (amines) > weak Lewis acids (alcohols, phenols) > strong Lewis acids 
(carboxylic acids). Also the retention increases as the number of carbon atoms increases. 
      As a general rule the retention increases with increasing contact area between sample 
molecule and stationary phase i.e. with increasing number of water molecules, which are 
released during the adsorption of a compound. Branched chain compounds are eluted more 
rapidly than their corresponding normal isomers. 
      In reversed phase systems the strong attractive forces between water molecules arising 
from the 3-dimentional inter molecular hydrogen bonded network, from a structure of water 
that must be distorted or disrupted when a solute is dissolved. Only higher polar or ionic 
solutes can interact with the water structure. Non- polar solutes are squeezed out of the 
mobile phase and are relatively insoluble in it but with the hydrocarbon moieties of the 
stationary phase. 
      Chemically bonded octadecyl silane (ODS) an alkaline with 18 carbon atoms is the most 
popular stationary phase used in pharmaceutical industry. Since most pharmaceutical 
compounds are polar and water soluble, the majority of HPLC methods used for quality 
assurance, decomposition studies, quantitative analysis of both bulk drugs and their 
formulations use ODS HPLC columns. The solvent strength in reversed phase 
chromatography is reversed from that of adsorption chromatography (silica gel) as stated 
earlier. Water interacts strongly with silanol groups, so that, adsorption of sample molecules 
become highly restricted and they are rapidly eluted as a result. Exactly opposite applies in 
reversed phase system; water cannot wet the non-polar (hydrophobic) alkyl groups such as 
C18 of ODS phase and therefore does not interact with the bonded moiety. Hence water is the 
weakest solvent of all and gives slowest elution rate. The elution time (retention time) in 
reversed phase chromatography increases with increasing amount of water in the mobile 
phase.  
Partition chromatography 
                                     Partition chromatography was the first kind of chromatography 
that chemists developed. The partition coefficient principle has been applied in paper 
chromatography, thin layer chromatography, gas phase and liquid-liquid applications. 
Partition chromatography uses a retained solvent, on the surface or within the grains or fibers 
of an “inert” solid supporting matrix as with paper chromatography, or takes advantage of 
some additional columbic and/or hydrogen donor interaction with the solid support. 
Molecules equilibrate (partition) between a liquid stationary phase and the eluent separate 
analytes based on the polar differences is known as Hydrophilic Interaction Chromatography 
(HILIC). Partition HPLC has been used historically on unbounded silica or alumina supports. 
Each works effectively for separating analytes by relative polar differences. However, HILIC 
has the advantage of separating acidic, basic and neutral solutes in a single chromatogram. 
Eg CPC (Centrifugal Partition Chromatography), GLC (Gas Liquid Chromatography), and 
paper partition chromatography. 
Displacement Chromatography 
                                    The basic principle of displacement chromatography is a 
molecule with a high affinity for the chromatography matrix (the displacer) will compete 
effectively for binding sites and thus displace all molecules with lesser affinities. In elution 
mode, substances typically emerge from a column in narrow Gaussian peaks. Wide 
separation of peaks, preferably to baseline, is desired in order to achieve maximum 
purification. The speed at which any component of a mixture travels down the column in 
elution mode depends on many factors. But for two substances to travel at different speeds 
and thereby be resolved there must be substantial differences in some interaction between the 
bio molecules and the chromatography matrix. Operating parameters are adjusted to 
maximize the effect of this difference. In many cases, baseline separation of the peaks can be 
achieved only with the gradient elution and low column loadings. Thus, two drawbacks to 
elution mode chromatography, especially at preparative scale, are operational complexity, 
due to gradient solvent pumping, and low throughput, due to low column loadings. 
Displacement chromatography has advantages over elution chromatography in that 
components are resolved into consecutive zones of pure substances rather than “peaks”. 
Based on principle of separation 
Adsorption chromatography 
                            When a mixture of compounds (adsorbate) dissolved in the mobile 
phase (eluent) moves through a column of stationary phase (adsorbent) they travel according 
to their relative affinities. The compound which has more affinity towards stationary phase 
travels slower and if less affinity towards stationary phase travels faster. 
Eg GSC (gas-solid chromatography), TLC (thin layer chromatography), C.C (column 
chromatography), HPLC (High performance liquid chromatography). 
Ion exchange chromatography 
                                   Ion-exchange chromatography involves a solid stationary phase 
with anionic or cationic groups on the surface to which solute molecules of opposite charge 
are attracted. It is the process by which a mixture of similar charged ions can be separated 
using ion exchange resin. There is a reversible exchange of ions between the ions present in 
the column. And those present in the ion exchange resin. For cations, cation exchange resin, 
for anions, an anion exchange resin is used. 
Eg Cationic exchangers 
                   Natural Inorganic - Zeolite, Clays. 
                   Natural Organic - Peat, Lignite, Neutral Sulphonated coal. 
                   Synthetic Inorganic - MgO, SiO2. 
                   Synthetic Organic - Polymeric Resin matrix containing acidic exchange resins. 
Eg Anionic exchangers 
                  Natural Inorganic - Dolamite. 
      Synthetic Inorganic - Heavy metal silicates. 
      Synthetic Organic - Polymeric Resin matrix containing basic exchange resins. 
Size Exclusion chromatography  
                                   Size-exclusion chromatography involves a solid stationary 
phase with controlled pore size. Solutes are separated according to their molecular size, the 
large molecules enable to enter the pores eluting first. It is the process by which mixture of 
compounds with molecular sizes are separated by using gels. The gel used acts as molecular 
sieve. It can be separated by steric and diffusion effects of pores in the gels. The compound 
can separate according to the molecular sizes and the stationary phase is porous matrix.  
Eg Separation of proteins, and polysaccharides. 
Chiral phase chromatography 
                                     In this type of chromatography separation of optical isomers 
can be done by using chiral stationary phase i.e. levo and dextro form can be separated by 
using chiral stationary phases. 
Eg chemically bonded silica gel. 
Ion pair chromatography 
                                          In this chromatography, a reverse phase column is 
converted temporarily into ion exchange column by using ion pairing agents like pentane or 
hexane. 
 Based on elution technique 
Isocratic elution 
                                                      In this elution technique, a single mobile phase is pumped 
to the column throughout the analysis. The composition or the concentration of the mobile 
phase is not altered throughout the run. 
                                       
                                                            Isocratic mode 
 
Gradient elution 
                                                     In gradient elution, the mobile phase is changed at regular 
time intervals depending upon the sample of analysis. The concentration of the stronger 
mobile phase is increased during the run. Preparative chromatography is usually carried out 
by gradient elution technique. 
                                     
 
                                                                Gradient mode 
 
 
Based on the scale of operation4 
Analytical HPLC  
                                              Where it is used analysis of samples are done. But recovery of 
samples for reusing is normally not done, since the sample used is very low. 
Eg microgram quantities. 
Preparative HPLC 
                                      Where the individual fractions of pure compounds can be 
collected using fraction collector. And the collector samples are reused.  
Eg separation of few grams of mixtures. 
Based on the type of analysis 
Qualitative Analysis  
                                          Which is used to identify the compound, detect the presence of 
impurities, to find out the number of components, etc. this is done using retention time 
values? 
Quantitative Analysis  
                            This is done to determine the quantity of the individual or several 
components in a mixture. This is done by comparing the peak area of the standard and 
sample. Chromatographic methods can be classified most practically according to the 
stationary and mobile phases, as shown in the table.  
Stationary 
phase 
Mobile 
phase 
                                  
Method 
Solid Liquid Adsorption column, thin-layer, ion exchange, High 
performance liquid chromatography. 
Liquid Liquid 
Gas 
Partition, column, thin-layer, HPLC, paper chromatography. 
Gas – Liquid Chromatography. 
Table-1 Classification of Chromatographic methods 
                                             The importance of Chromatography is increasing rapidly in 
pharmaceutical analysis. The exact differentiation, selective identification and quantitative 
determination of structurally closely related compounds are possible with chromatography. 
Another important field of application of chromatographic methods is the purity testing of 
final products and intermediates (detection of decomposition products and by-products). As a 
consequence of the above points, chromatographic methods are occupying an ever-expanding 
position in the latest editions of the pharmacopoeias and other testing standards. 
      The modern form of column chromatography has been called high performance, high 
pressure, high-resolution and high-speed liquid chromatography. 
      High-Performance Liquid Chromatography (HPLC) is a special branch of column 
chromatography in which the mobile phase is forced through the column at high speed.  As a 
result the analysis time is reduced by 1-2 orders of magnitude relative to classical column 
chromatography and the use of much smaller particles of the adsorbent or support becomes 
possible increasing the column efficiency substantially.   
      The essential equipment consists of an eluent, reservoir, a high-pressure pump, and an 
injector for introducing the sample, a column containing the stationary phase, a detector and 
recorder. The development of highly efficient micro particulate bonded phases has increased 
the versatility of the technique and has greatly improved the analysis of multi component 
mixtures. 
      The systems used are often described as belonging to one of four mechanistic types, 
adsorption, partition, ion exchange and size-exclusion. Adsorption chromatography arises 
from interaction between solutes on the surface of the solid stationary phase. Partition 
chromatography involves a liquid stationary phase, which is immiscible with the eluent and 
coated on an inert support. Adsorption and partition systems can be normal phase (stationary 
phase more polar than eluent) or reversed phase (stationary phase less polar than eluent). Ion-
exchange chromatography involves a solid stationary phase with anionic or cationic groups 
on the surface to which solute molecules of opposite charge are attracted. Size-exclusion 
chromatography involves a solid stationary phase with controlled pore size. Solutes are 
separated according to their molecular size, the large molecules enable to enter the pores 
eluting first.   
Chromatography parameters 5 
      Calculating the following values (which can be included in a custom report) used to 
access overall system performance. 
1. Relative retention  
2. Theoretical plates  
3. Capacity factor  
4. Resolution  
5. Peak asymmetry  
6. Plates per meter  
7. Back pressure. 
      The parameters used to calculate these system performance values for the separation of 
two chromatographic components. (Note: Where the terms W and t both appear in the same 
equation they must be expressed in the same units). 
Relative retention (Selectivity) 
The relative retention is calculated as an estimate using the following formula: 
α = (t2 - ta) / (t1 - ta) 
Theoretical plates (column efficiency)  
It measures the band spreading of a peak. When band spread in smaller, the number of 
theoretical plates is higher. It indicates a good column and system performance. 
n = 16 (t / W) 2 
Capacity factor 
This factor determines the retention of a solute and can be calculated from the chromatogram 
using the following formula 
k' = (t2 – ta)/ ta 
A low k' value indicates that the peak elutes close to the solvent front, which may 
compromise selectivity. A minimum k' value of 1 is recommended for the peak of interest. 
 The retention time of the test substance can be varied, if necessary, by changing the 
relative proportion or composition of solvents in the mobile phase. Generally, an increase in 
the proportion of a more polar solvent will lead to a shorter retention time on a normal-phase 
column and a longer retention time on a reserved-phase column. 
Resolution 
It is measure of the extent of separation of two compounds and the baseline separation is 
achieved. The resolution between two peaks of similar height in a chromatogram can be 
calculated using the following formula: 
            R = 2 (t2 - t1) / (W2 + W1) 
To ensure the accuracy of quantitative analysis, the R value of the analyte peak with the 
adjacent peak must be larger than 1.5, unless otherwise specified. (tR1 tR2 
W1 W2  ) 
                                                       
Peak asymmetry (Tailing factor) 
The Tailing Factor T, a measure of peak symmetry is unity for perfectly symmetrical peaks 
and its value increases as tailing becomes more pronounced. In some cases, values less than 1 
may be observed. As peak asymmetry increases integration and hence precision becomes less 
reliable. 
                                                       T = W0.05 / 2f 
Where, W0.05 = peak width at 5% height 
f = distance from peak front to apex point at 5% height. 
The accuracy of Quantitation decreases with increase in peak tailing because of the 
difficulties encountered by the integrator in determining where / when the peak ends and 
hence the calculation of the area under the peak. 
Plates per meter 
                             Plates per meter can be expressed as 
                                                                N = n / L 
Backpressure 
                                          The pressure required to pump the mobile phase through the 
column. It is related to mobile phase viscosity (η), flow rate (F), column length (L), and 
diameter (dc), and particle size (dp) by the following equation: 
                                                     ΔP α FLη / dp2 dc2 
HETP (High Equivalent Theoretical Plates)   
                                                     A theoretical plate can be of any height, which decides the 
efficiency of separation. If HETP is less the column is more efficient. If HETP is more, the 
column is less efficient. The height equivalent to a theoretical plate (HETP) is given by 
                                                               HETP = L/n 
Where, α = Relative retention. 
t2 = Retention time of the peak of interest measured from point of injection. 
t1 = Retention time of the reference peak measured from point of injection. 
ta = Retention time of an inert peak not retained by the column, measured from point 
of injection. 
n = Theoretical plates. 
t = Retention time of the component. 
W = Width of the base of the component peak using tangent method. 
K' = Capacity factor. 
R = Resolution between a peak of interest (peak 2) and the peak preceding it  
             W2 = Width of the base of component peak 2. 
             W1 = Width of the base of component peak 1. 
             T = Peak asymmetry, or tailing factor. 
            W0.05 = Distance from the leading edge to the tailing edge of the peak, measured at a   
point 5 % of the peak height from the baseline. 
             f = Distance from the peak maximum to the leading edge of the peak. 
             N = Plates per meter. 
            L = Column length, in meters.  
The HPLC process starts with the preparation of sample and placing in a vial .the organic 
phase and buffer are selected and the temperature for the analysis should be set. the injection 
volume vial number should be set and the chromatogram development occurs based on the 
affinity towards the stationary phase. 
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HPLC METHOD VALIDATION 6 
1.3. ICH GUIDELINES 
According to USP General Chapter <1225> “Validation is the process of providing 
documented evidence that the method does what it is intended to do”. In other words the 
process of method validation ensures that the proposed analytical methodology is accurate, 
specific, reproducible and rugged for its intended use  
According to the FDA Guidelines on General Principles of Process Validation, 
process validation is defined, ‘‘ As establishing documented evidence, which provides a high 
degree of assurance, that a specific process will consistently produce a product meeting its 
predetermined specifications and quality characteristics.’’  
According to ICH Guidelines Validation of an Analytical procedure is to 
demonstrate that it is suitable for its intended purpose.  
Method validation can be defined as (ICHQ.2B) “Establishing documented evidence, 
which provides a high degree of assurance that a specific activity will consistently produce a 
desired result or product meeting its predetermined specifications and quality characteristics”. 
      Method validation is an integral part of the method development; it is the process of 
demonstrating that analytical procedures are suitable for their intended use and that they 
support the identity, quality, purity, and potency of the drug substances and drug products. 
Simply, method validation is the process of proving that an analytical method is acceptable 
for its intended purpose. 
      Method Validation, however, is generally a one-time process performed after the method 
has been developed to demonstrate that the method is scientifically sound and that it serves 
the intended analytical purpose. 
TYPES OF ANALYTICAL PROCEDURES TO BE VALIDATED7 
-     Identification tests. 
-     Quantitative tests for impurities content 
-     Limit tests for the control of impurities 
-     Quantitative tests of the active moiety in samples of drug substance or drug 
product or other selected component(s) in the drug product. 
Method Validation is required for the following 
 Method validation required for assuring the quality identity purity. 
 Achieving the acceptance of the product by the international agencies. 
 Mandatory requirements for the registration of Pharmaceuticals pesticides and 
formations. 
 Validation methods are only acceptable for under taking sufficiency testing.  
 
Identification tests are indented to ensure the identity of analyte in a sample. This is 
normally achieved by comparison of sample chromatograms to that of a reference standard. 
Testing for impurities can be either a qualitative or quantitative limit test for the impurity 
in the sample. 
      All the variables of the method should be considered, including sampling procedure, 
sample preparation, chromatographic separation, detection and data evaluation. For 
chromatographic methods used in analytical applications there is more consistency in 
validation practice with key analytical parameters. 
1.4. STATISTICAL PARAMETERS FOR METHOD VALIDATION8 
 Recovery  
 Response function. 
 Sensitivity 
 Precision. 
 Accuracy. 
 Calibration. 
 Standard deviation of slope. 
 Standard deviation of intercept. 
 Correlation coefficient. 
 Linearity and sensitivity of the method. 
 Limit of detection. 
 Limit of quantization. 
 Ruggedness. 
 Robustness. 
 Stability 
 Range . 
Recovery 
                                        The absolute recovery of analytical method is measured as the 
response of a processed spiked matrix standard expressed as a percentage of the response of 
pure standard, which has not been subjected to sample pre-treatment and indicates whether 
the method provides a response for the entire amount of analyte that is present in the sample. 
It is best established by comparing the responses of extracted samples at low, medium and 
high concentrations in replicates of at least 6 with those non-extracted standards, which 
represent 100 % recovery.   
Absolute recovery = Response of an analyte spike into matrix (processed) X  100                       
          Response of analyte of pure standard (unprocessed)  
If an internal standard is used, its recovery should be determined independently at the 
concentration levels used in the method.  
Response function 
                                     In chromatographic methods of analysis, peak area or peak height may 
be used as response function to define the linear relationship with concentration known as the 
calibration model. It is essential to verify the calibration model selected to ensure that it 
adequately describes the relationship between response function (Y) and concentration (X). 
 
Sensitivity 
                                      The method is said to be sensitive if small changes in concentration 
cause large changes in response function. The sensitivity of an analytical method is 
determined from the slope of the calibration line. The limits of quantification (LOQ) or 
working dynamic range of bio analytical method are defined as the highest and lowest 
concentrations, which can determined with acceptable accuracy. It is suggested that, this be 
set at ± 15% for both the upper and lower limit of quantitation respectively. Any sample 
concentration that falls outside the calibration range cannot be interpolated from the 
calibration line and extrapolation of the calibration curve is discouraged. If the concentration 
is over range, the sample should be diluted in drug-free matrix and re-assayed.  
Precision 
                         The closeness of agreement (degree of scatter) between a series of 
measurements obtained from multiple sampling of the same homogenous sample under the 
prescribed conditions. Precision may be considered at three levels:  
             Repeatability/ System Precision. 
             Reproducibility/ Method Precision 
             Ruggedness/ Intermediate Precision. 
The purpose of carrying out a determination is to obtain a valid estimate of a ‘true’ value. 
When one considers the criteria according to which an analytical procedure is selected, 
precision and accuracy are usually the first time to come to mind. Precision and accuracy 
together determine the error of an individual determination. They are among the most 
important criteria for judging analytical procedures by their results.  
      Precision refers to the reproducibility of measurement within a set, that is, to the scatter of 
dispersion of a set about its central value. The term ‘set’ is defined as referring to a number 
(n) of independent replicate measurements of some property. One of the most common 
statistical terms employed is the standard deviation of a population of observation. Standard 
deviation is the square root of the sum of squares of deviations of individual results for the 
mean, divided by one less than the number of results in the set. The standard deviation S, is 
given by 
                                                 S =  
Standard deviation has the same units as the property being measured. 
      The square of standard deviation is called variance (S2). Relative standard deviation is the 
standard deviation expressed as a fraction of the mean, i.e., S/x. It is sometimes multiplied by 
100 and expressed as a percent relative standard deviation. It becomes a more reliable 
expression of precision.  
% Relative standard deviation = S × 100 / x 
Acceptance: %RSD should be not more than 2% for assay. 
Accuracy 9 
           Accuracy of analytical method is ‘Measure of how close the experimental value to the 
true value.’ 
                  Accuracy normally refers to the difference between the mean set of results and the 
true value for the quantity measured. According to IUPAC accuracy relates to the difference 
between results (or mean) and the true value. For analytical methods, there are two possible 
ways of determining the accuracy, absolute method and comparative method. 
                  Accuracy is best reported as percentage bias, which is calculated from the 
expression.  
                                   
                            Since for real samples the true value is not known, an approximation is 
obtained based on spiking drug – free matrix to a nominal concentration. The accuracy of 
analytical method is then determined at each concentration by assessing the agreement 
between the measured and nominal concentrations of the analytes in the spiked drug – free 
matrix sampler.   
                                 Accuracy studies is evaluated by recovery studies in which known 
amount of the drug substances is added to the previously analyzed pharmaceutical 
preparations of the drug and tested for the added drug. 
            Acceptance: The method is considered as accurate if average recovery is in between 
97.0% to 103.0% for assay 
Calibration 
                                  Calibration is the most important step in bioactive compound analysis. 
A good precision and accuracy can only be obtained when a good calibration procedure is 
adopted. In the spectrophotometric methods, the concentration of a sample cannot be 
measured directly, but is determined using another physical measuring quantity ‘y’ 
(absorbance of a solution). An unambiguous empirical or theoretical relationship can be 
shown between this quantity and the concentration of an analyte. The calibration between y = 
g (x) is directly useful and yields by inversion of the analytical calculation function. 
          The calibration function can be obtained by fitting an adequate mathematical model 
through the experimental data. The most convenient calibration function is linear, goes 
through the origin and is applicable over a wide dynamic range. In practice, however, many 
deviations from the ideal calibration line may occur. For the majority of analytical techniques 
the analyst uses the calibration equation. 
                                                    Y = a + bx. 
      In calibration, univariate regression is applied, which means that all observations are 
dependent upon a single variable X. 
Standard deviation of slope (Sb) 
        The standard deviation of slope is proportional to standard error of estimate and 
inversely proportional to the range and square root of the number of data points. 
                                    Sb =                                        
Where Xi is the arithmetic mean of Xi values. 
Standard deviation of intercept (Sa) 
      Intercept values of least squares fits of data are often to evaluate addeditive errors 
between or among different methods. 
                                           Sa =       
                                        Where Xi denote the arithmetic mean of xi, values. 
Correlation Coefficient (r)  
       The correlation coefficient r(x, y) is more useful to express the relationship of the chosen 
scales. To obtain a correlation coefficient the covariance is divided by the product of the 
standard deviation of x and y. 
                 r=         
 Linearity and sensitivity of the method  
      Knowledge of the sensitivity of the color is important and the following terms are 
commonly employed for expressing sensitivity.  According to Bouger- Lambert – Beer’s law, 
log intensity of incident radiations 
                                          
                                                    The absorbance (A) is proportional to the concentration (c) 
of the absorbing species, if absorptivity (Î) and thickness of the medium (t) are constant. 
When c is in moles per liter, the constant is called molar absorptivity. Beer’s law limits and 
Imax values are expressed as µg ml-1 and mole-1 cm-1 respectively. 
      Sandell’s sensitivity refers to the number of µg of the drug to be   determining, converted 
to the colored product, which in a column solution of cross section 1cm2 shows an 
absorbance of 0.001 (expressed as µg cm-2).  
 
 
Limit of detection10 
                                      The Detection Limit of an individual analytical procedure is the 
lowest amount of analyte in a sample which can be detected but not necessarily qualtitated as 
an exact value. The detection limit (LOD) may be expressed as 
                                                   LOD = 3.3σ/S 
Where, σ = the standard deviation of the response. 
              S = the slope of the calibration curve (of the analyte. 
limit of quantization 
              LOQ is defined as the lowest concentration of the substance (analyte) in a sample 
that can be estimated quantitatively with acceptable precision, accuracy and reliability by a 
given method under stated experimental conditions. Quantitation Limit (LOQ) may be 
expressed as 
LOQ = 10 σ /S 
Where, σ = the standard deviation of the response. 
             S = the slope of the calibration curve (of the analyte). 
Ruggedness 
                                Method Ruggedness is defined as the reproducibility of results when the 
method is performed under actual use conditions. This includes different analysts, 
laboratories, columns, instruments, source of reagents, chemicals, solvents etc. Method 
ruggedness may not be known when a method is first developed, but insight is obtained 
during subsequent use of that method.   
Acceptance: %RSD should not be more than 2.0% for assay. 
Robustness 
                               The concept of robustness of an analytical procedure has been defined 
by the ICH as “a measure of its capacity to remain unaffected by small but deliberate 
variations in method parameters providing an indication of reliability during normal usage”. 
The robustness of a method is the ability to remain unaffected by small changes in parameters 
such as pH of the mobile phase, temperature, %organic solvent strength and buffer 
concentration etc. to determine the robustness of the method experimental conditions were 
purposely altered and chromatographic characters were evaluated. System suitability 
parameters are to be met at different conditions. 
                                            Validation parameters for robustness 
                    Parameter Variation to be checked 
Flow rate ± 0.2 mL/min 
   Column temperature ±5˚C 
pH variation ±0.2 
Mobile phase composition ±5% 
Table-2 
Stability 
                               To generate reproducible and reliable results, the samples, standards and 
reagents used for the HPLC method must be stable for a reasonable time (e.g. one day, one 
week, one month etc, depending upon need). For example, the analysis of even a single 
sample may require ten or more chromatographic runs to determine the system suitability, 
including standard concentrations to create a working analytical curve and duplicate or 
triplicate injections of the sample to be assayed.  
Range  
                                    The range of a method can be defined as the upper and lower 
concentrations for which the analytical method has adequate accuracy, precision and 
linearity. The range of concentrations examined will depend on the type of method and its 
use. 
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Drug profile 
DRUG PROFILE 
SIMVASTATIN11 
                                            A synthetic analog of lovastatin (antilipidemic). 
CHEMICAL STRUCTURE 
                           
                                                         SIMVASTATIN 
CHEMICAL FORMULA   -    C25H38O5. 
CHEMICAL NAME -     (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-
6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl 1,2, 
3,7,8,8a-hexahydronaphthalen-1-yl2,2 dimethylbutane 
ate. 
MOLECULAR WEIGHED  -           418.56622 
SOLUBILITY -            practically insoluble in water, and freely   
soluble in chloroform, methanol and ethanol. 
λMAX    -         238nm. 
PKa     -         4.3 
MELTING POINT   -         139ᵒC. 
STORAGE CONDITION   -  It should be stored in well-closed, light- resistant    
containers at 5-30 deg C. 
THERAPEUTIC ACTIVITY - Used in the treatment of hypercholesterolemia. 
Hydroxy methyl CoA reductase, hypolipidemic agent. 
DESCRIPTION   -   white powder. 
M.O.A - The 6-membered lactone ring of Simvastatin is 
hydrolyzed in vivo to generate the Dihydroxy acid, an 
active metabolite structurally similar to HMG-CoA 
(hydroxy CoA). Once hydrolyzed, Simvastatin 
competes with HMG-CoA for HMG-CoA1 microsomal 
enzyme. Interference with the activity of this enzyme 
reduces the mevalonic acid, a precursor of cholesterol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                   SITAGLIPTIN12 
CHEMICAL STRUCTURE 
                                                                    
                                                     SITAGLIPTIN    
 CHEMICAL FORMULA  -           C16H15F6N5O .                
CHEMICAL NAME                        -    (3R)-3-amino-1-[3-(trifluoromethyl)-
5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-
yl]-4-(2,4,5-trifluorophenyl)butan-1-one . 
 MOLECULAR WEIGHED  -            407.3136. 
SOLUBILITY                                   -  It is soluble in water and N,N-dimethyl  
formamide; slightly soluble in methanol; very  
slightly soluble in ethanol, acetone, and  
acetonitrile; and insoluble in isopropanol and  
isopropyl acetate. 
 λ MAX    -   268nm. 
PKa      -    7.7. 
MELTING POINT   - 252.1ᵒC 
STORAGE CONDITION  -           stored in well closed container.  
THERAPEUTIC ACTIVITY -  Anti diabetic drug. 
DESCRIPTION                                -          white to off-white, crystalline, nonhygro scopic 
powder.                                                                                                                             
M.O.A(13)                                                  -          Sitagliptin is a Dipeptidyl peptidase-4( DPP-4) 
inhibitor, which is believed to exert its actions in 
patients with type2 diabetes by slowing the 
inactivation of incretin hormones. 
Concentrations of the active intact hormones are 
increased by SITAGLIPTIN, thereby increasing 
and prolonging the action of these hormones. 
Incretin hormones, including glucagon-like 
peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP), are released by 
the intestine throughout the day, and levels are 
increased in response to a meal. These hormones 
are rapidly inactivated by the enzyme, DPP-4. 
The incretins are part of an endogenous system 
involved in the physiologic regulation of glucose 
homeostasis. 
When blood glucose concentrations are normal 
or elevated, GLP-1 and GIP increase insulin 
synthesis and release from pancreatic beta cells 
by intracellular signaling pathways involving 
cyclic AMP. GLP-1 also lowers glucagon 
secretion from pancreatic alpha cells, leading to 
reduced hepatic glucose production. By 
increasing and prolonging active incretin levels, 
SITAGLIPTIN increases insulin release and 
decreases glucagon levels in the circulation in a 
glucose-dependent manner. Sitagliptin 
demonstrates selectivity for DPP-4 inhibitor. 
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 LITERATURE REVIEW 
1. Sreelakshmy.N14 et.al (2011) developed a reverse phase high performance liquid 
chromatographic method for the simultaneous determination of Simvastatin and 
ezetimibe in tablet dosage form. The separation was effected on a symmetry C8 (4.68 
x150mm,5 Âµm)using a mobile phase consisting of phosphate buffer and acetonitrile 
(50:50v/v)at a flow rate of 1ml/min. The detection was made at 236 nm. The retention 
time for ezetimibe and Simvastatin were 4.4 and 8.4 respectively. Caliberation curve 
were linear over the ranges of 10-50Âµg/ml for both ezetimibe and Simvastatin. The 
mean recovery was found to be 102.7% and 99.6% for ezetimibe and Simvastatin 
respectively. The correlation coefficients for both the components were close to. The 
developed method was validated according to ICH guidelines. 
2. Pravish Kumar Tiwari 15 et.al (2010) has developed a simple, sensitive and validated 
HPTLC method to determine Niacin and Simvastatin simultaneously in synthetic 
mixture form. Chromatographic separation was achieved on a RP18 plate using a 
mixture of Methanol: Water: Acetic acid (60:40:0.1) at a wavelength of 237 nm. 
Linearity of the method was found to be in the concentration range of 5000.0-25000.0 
μg/ml for niacin and 100.0-500.0 μg/ml for Simvastatin with correlation coefficient 
greater than 0.999. 
3. Jat R K16 et.al (2012) developed a simple, accurate rapid and precise RP-HPLC 
method and validated for determination of Simvastatin in bulk drug. The RP-HPLC 
separation was achieved on Promosil C-18, (250 mm, 4.6 mm, 5µm) using mobile 
phase buffer: methanol ph 6.8 (96: 4 v/v) at flow rate of 1.0 ml/min at ambient 
temperature. The retention times were 9.546 min. for Simvastatin. Calibration plots 
were linear over the concentration range 1-50µg/ml. Quantification was achieved with 
photodiode array detection at 254 nm over the concentration range of 1-50 µg/ml.  
4. Stephen Rathinaraj.B17 et.al (2010) developed a simple, precise, accurate and rapid 
high-performance thin-layer chromatographic method and validated for the estimation 
of Simvastatin and ezetimibe simultaneously in combined dosage forms. The stationary 
phase used was precoated silica gel 60F 254. The mobile phase used was a mixture of 
chloroform: benzene: methanol: acetic acid (6.0:3.0:1.0:0.1 v/v/v/v). The detection of 
spots was carried out at 250 nm. The method was validated. The calibration curve was 
found to be linear between 0.8 and 4.0 μg/spot for Simvastatin and 0.1 and 1.0 μg/spot 
for ezetimibe. The limit of detection and the limit of quantification for Simvastatin were 
found to be 170 ng/spot and 570 ng/spot respectively, and for ezetimibe, 20 ng/spot and 
70 ng/spot respectively. 
5. Varsha Balkrishna Mane18 et.al (2010) developed a versatile, accurate, precise and 
economic method for simultaneous determination of Simvastatin and ezetimibe in fixed 
dose combination products. The absorbance values at 238.2 nm and 247.6 nm and 
243.3nm (isoabsorptive point) were used for the estimation of Simvastatin and 
ezetimibe, respectively without mutual interference. This method obeyed Beer’s law in 
the concentration range of 3–18 μg /ml for Simvastatin and 5-30 μg /ml for ezetimibe. 
The results of analyses have been validated statistically for linearity, accuracy and 
precision, LOD and LOQ of the proposed method. 
6. Praveen Kumar S. N19et.al (2012) developed a simple, sensitive and validated HPLC 
method to determine Simvastatin in bulk drug and pharmaceutical formulation. The 
chromatographic method was achieved on a C18 column (150x4.6 mm, 2.7 μm) using a 
mixture of methanol and 0.1% ortho phosphoric acid in water (10:90) at a wavelength 
of 238 nm. The retention time of Simvastatin was found to be 3.106 min. The method 
was found to show good linearity in the concentration range of 5.0 – 60.0 μg/ml of 
Simvastatin with correlation co-efficient of 0.9999. Accuracy was between 97.45% and 
98.32%.  
7. Nataraj k.s20et.al (2012) developed a  Reverse phase high performance liquid 
chromatographic (RP-HPLC) method  for the simultaneous estimation of ezetimibe 
(EZT) and Simvastatin (SMV) in marketed tablet formulation .The determination was 
carried out on Inertsil ODS-3V, (150 × 4.6 mm, 5µ) column and 0.1% orthophosphoric 
acid in Milli Q water adjust PH 4.2 with triethylamine, methanol and acetonitrile 
(45:15:40) used as a mobile phase in gradient technique, at a flow rate of 1.8ml/min, the 
detection was carried out at 238nm. Retention time of EZT and SMV were found to be 
5 and 10.50 min, respectively. The method has been validated according to ICH Q2 
(R1) guidelines. Linearity for EZT and SMV were found in the range of 5ppm-15ppm 
for both drugs. The correlation coefficient (r2) for EZT and SMV were found to be 
0.9999 and 0.9998, respectively. The mean recoveries obtained for EZT and SMV were 
found to be 101% and 101.5%, respectively .Developed method was found to be 
accurate, precise, selective and rapid for simultaneous estimation of EZT and SMV in 
tablets. 
8. Effat souri21et.al (2010) has developed a rapid and sensitive derivative 
spectrophotometric method for analysis of these drugs in combined dosage forms. A 
first order derivative spectrophotometric method was developed for simultaneous 
determination of Simvastatin and ezetimibe using zero-crossing technique. The 
measurements were carried out at 219 and 265 nm for Simvastatin and ezetimibe 
respectively. The described method was found to be linear (r2>0.999) over the range of 
2-40 μg/mL for Simvastatin in the presence of 10μg/mL ezetimibe at 219 nm and in the 
range of 1-20 μg/mL of ezetimibe in the presence of 20 μg/mL of Simvastatin at 265 
nm. The within-day and between-day precision values for both drugs were less than 3% 
(CV). 
9. Madhukar A22 et.al (2012) developed a analytical method suitable for validation of 
Simvastatin by reversed Phase High Performance liquid chromatography (RP-HPLC) 
method. The method utilized RP-HPLC (Younglin HPLC with UV-detector) model and 
a column, 150mm 4.6 mm, 5m (Symmetry, ODS- 3V, 150mm,4.6mm, 5m). The mobile 
phases were comprised of Acetonitrile and (0.02M) Buffer pH 3.5 (60:40 v/v). 
Validation experiments were performed to demonstrate System suitability, precision, 
linearity and Range, Accuracy study, stability of analytical solution and robustness. The 
method was linear over the concentration range of 1-150 mg/ML-1. The method 
showed good recoveries (98.2 – 104.3%). 
10. Dhaneshwar.s.s23et.al (2008) developed a simple, precise, and accurate HPTLC 
method for simultaneous estimation of the compounds as the bulk drugs and in the 
tablet dosage form. Chromatographic separation was performed on aluminium-backed 
silica gel 60 F254 plates with 8:2 (v/v) toluene -2- propanol as mobile phase. The 
separated spots were densitometrically evaluated at 240 nm. The drugs were 
satisfactorily resolved with RF values 0.48 ± 0.01 and 0.53 ± 0.01for Simvastatin and 
ezetimibe, respectively. The accuracy and reliability of the method were assessed by 
determination of validation data for linearity (0.4–2.0 μg per spot for both Simvastatin 
and ezetimibe), precision (intra-day RSD 0.51–1.04%, inter-day RSD 0.34–1.11% for 
Simvastatin; intra-day RSD 0.47–0.61%, inter-day RSD 0.31–0.61% for ezetimibe), 
accuracy (98.50 ± 0.23 for Simvastatin and 98.99 ± 0.38 for ezetimibe), and specificity, 
in accordance with ICH guidelines.  
 
11. Jyothirmayee.M24 et.al (2012) developed a new method based on oxidative coupling 
of Simvastatin with MBTH (3-Methyl-2-benzothiazolinone hydra zone hydrochloride 
monohydrate) as a chromogenic derivatizing reagent in presence of Ferric chloride, 
resulting green color complex with a suitable absorption at 628nm. Optimization studies 
showed that the coupling reaction is very fast and completed in less than 1 minute. The 
coupled complex formed exhibits absorption maximum at 628 nm. The assays were 
linear over the concentration range of 2-8 μg/ml and reproducible. Linear relationship 
with good correlation coefficients 0.994 were found between absorbance and 
corresponding concentrations of drug. The reliability and performance of proposed 
methods was validated statistically the percentage recovery ranged from 100.36-
101.75% respectively.  
12. Srinivas .c 25 et.al (2012) developed a simple, rapid, sensitive, reverse phase isocratic 
RP-HPLC method for estimation of Simvastatin in bulk and microemulsion 
formulation. The method was carried out using (Phenomenex Luna C18 5μm 
4.6×250mm (i.d) column) with mobile phase comprised of 0.1% Triethylamine buffer 
(pH 7.5): Acetonitrile (20:80v/v). The flow rate was set at 1.0 ml/min and effluent was 
detected at 238nm, The retention time of Simvastatin was found to be 8.6 minute. The 
method developed was validated for specificity, accuracy, precision, linearity and limit 
of detection, limit of quantification, robustness and stability. The calibration curve was 
linear in the concentration range of 200-600 ng/ml with correlation coefficient of 0.999. 
LOD and LOQ were found to be 5ng/ml and 40ng/ml respectively. The percentage 
recovery for the Simvastatin was found to be 99.15% to 100.53% and the % RSD was 
found to be 0.980% (i.e <1%).  
13. Mohamed Salim26 et.al (2012) developed a novel, quick, reliable and simple capillary 
zone electrophoresis CZE method and validated for the simultaneous determination of 
Sitagliptin (SG) and metformin (MF) in pharmaceutical preparations. Separation was 
carried out in fused silica capillary (50.0 cm total length and 43.0 cm effective length, 
49 μm i.d.) by applying a potential of 15 KV (positive polarity) and a running buffer 
containing 60 mM phosphate buffer at pH 4.0 with UV detection at 203 nm. The 
samples were injected hydrodynamically for 3 s at 0.5 psi and the temperature of the 
capillary cartridge was kept at 25 °C. Phenformin was used as internal standard (IS). 
The method was suitably validated with respect to specificity, linearity, limit of 
detection and quantization, accuracy, precision, and robustness. The method showed 
good linearity in the ranges of 10–100 μg/mL and 50–500 μg/mL with limits of 
detection of 0.49, 2.11 μg/mL and limits of quantification of 1.48, 6.39μg/mL for SG 
and MF, respectively.  
14.  Bujji Babu27 et.al (2011) developed a simple, sensitive and accurate reversed phase 
high performance liquid chromatographic method for Enoxaparin sodium and 
Sitaglipitin drugs. Reversed phase chromatographic separation the above two drugs was 
performed a C18 column is used with different mobile phases of water, orthophosphoric 
acid, tetrahydrofuranan methanol, acetonitrile, sodiumdihydrogen phosphate, 
orthophosphoric acid respectively. The detection of wave length is 230 nm for 
Enoxaparin sodium and 270 nm for Sitagliptin .The percentage of recovery 99.5% for 
enoxaparin sodium and 97.6% for sitaglipitin. The proposed method is validated for 
linearity, accuracy, and precision, limit of detection (LOD) and limit of quantification 
(LOQ) as per the guide lines of Internationational Conference on Harmonization (ICH). 
15. RamziaI28 et.al (2011) developed a Simple, accurate and precise SpectroflourImetric 
and spectrophotometric methods and validated for the determination of Sitagliptin 
phosphate monohydrate (STG) and metformin HCL (MET). Zero order, first derivative, 
ratio derivative spectrophotometric methods and flourometric methods have been 
developed. The zero order spectrophotometric method was used for the determination 
of STG in the range of 50-300 μg mL−1. The first derivative spectrophotometric 
method was used for the determination of MET in the range of 2–12 μg mL−1 and STG 
in the range of 50-300 μg mL−1 by measuring the peak amplitude at 246.5 nm and 275 
nm, respectively. The first derivative of ratio spectra spectrophotometric method used 
the peak amplitudes at 232 nm and 239 nm for the determination of MET in the range 
of 2–12 μg mL−1. The flourometric method was used for the determination of STG in 
the range of 0.25-110 μg mL−1.  
16. RamziaI29 et.al (2011) developed a Simple, accurate and precise spectrophotometric 
methods for the determination of Sitagliptin and Vildagliptin in bulk and dosage forms. 
The proposed methods are based on the charge transferred complexes of Sitagliptin 
phosphate and Vildagliptin with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), 
7,7,8,8-tetracyanoquinodimethane (TC NQ) and tetrachloro-1,4-benzoquinone (p-
chloranil). All the variables were studied to optimize the reactions conditions. For 
Sitagliptin, Beer’s law was obeyed in the concentration ranges of 50-300 μg/ml, 20-120 
μg/ml and 100-900 μg/ml with DDQ, TCNQ and p-chloranil, respectively. For 
Vildagliptin, Beer’s law was obeyed in the concentration ranges of 50-300 μg/ml, 10-85 
μg/ ml and 50-350 μg/ml with DDQ, TCNQ and p-chloranil, respectively. The 
developed methods were validated and proved to be specific and accurate for the quality 
control of the cited drugs in pharmaceutical dosage forms. 
17. Bala sekaran.C30et.al (2010) developed a simple, sensitive and reproducible 
spectrophotometric method for the determination of Sitagliptin phosphate in bulk and in 
pharmaceutical formulations. The proposed method is based on condensation of the 
primary amino group of Sitagliptin phosphate with acetyl acetone and formaldehyde 
producing a yellow colored product, which is measured spectrophotometrically at 
430nm. The color was stable for about 1 hour. Beer’s law is obeyed over a 
concentration range of 5‐25 μg/ml. The apparent molar absorptivity and Sandell 
sensitivity values are 1.067 x 104 Lmol‐1cm‐1 and 0.0471 μgcm‐2 respectively.  
18. Parag Pathade31et.al (2011) developed a simple, sensitive, reproducible and cost 
effective stability indicating UV Spectrophotometric method for quantitative 
determination of Sitagliptin Phosphate in bulk and pharmaceutical formulations. The 
UV spectrum was scanned between 200 to 400 nm and 267 nm was selected as 
maximum wavelength for absorption. Beer’s law was obeyed in the concentration range 
of 10-100 mg/ml. Good accuracy (99.87-100.45%), precision (%RSD 1.3147-1.2957) 
were found, the method was successfully applied to the pharmaceutical dosage form 
containing the above-mentioned drug without any interference by the excipients. The 
limit of detection and limit of quantification was found to be 0.16μg/ml & 0.45μg/ml 
respectively. 
19. Jain Pritam32et.al (2011) developed a simple, rapid, accurate and economical First 
order UV-derivative spectrophotometric method for estimation of Sitagliptin from bulk 
and pharmaceutical formulation. The λmax of Sitagliptin in methanol and water was 
found to be 267 nm. The same spectrum was derivatised in to first order derivative; 
showed maximum   amplitude of the trough at 275 nm. The drug follows linearity in the 
concentration range 10-60 μg/ml with correlation coefficient value 0.998.  The 
proposed method was applied to pharmaceutical formulation and % amount of drug 
estimated 99.19 % was found in good agreement with th label claim. The accuracy of 
the method was checked by recovery experiment performed at three different levels i.e., 
80%, 100% and 120 %. The % recovery was found to be in the range 98.54%– 99.98%. 
The low values of % R.S.D. are indicative of the accuracy and reproducibility of the 
method. The precision of the method was studied as an intra-day, inter-day variations 
and repeatability. The % R.S.D. value less than 2 indicate that the method is precise. 
Ruggedness of the proposed method was studied with the help of two analysts.  
20.  Sumithra M33 et.al (2012) developed a simple, sensitive and rapid reverse phase high 
performance liquid chromatographic method for simultaneous estimation of Sitagliptin 
and Metformin. A BDS hypersil C18 column (250x4.0mm,5μ) was used with a mobile 
phase containing a mixture of phosphate buffer (Ph-4) and Acetonitrile and in the ratio 
of 60:40. The flow rate was 1.0ml/min and effluents were monitored at 260nm and 
eluted at 2.8min and 2.0min respectively. Calibration curve was plotted with a range 
from 2-12μg/ml for Sitagliptin and 20-120 μg/ml for Metformin.  
21. Chellu S. N. Malleswararao 34 et.al (2012) developed a rapid, specific, accurate and 
precise reverse phase ultra performance liquid chromatographic (UPLC) method for the 
simultaneous determination of Sitagliptin phosphate mono-hydrate and Metformin 
hydrochloride in pharmaceutical dosage forms. The chromatographic separation was 
achieved on Aquity UPLC BEH C8 100 x 2.1 mm, 1.7 μm, column using a buffer 
consisting of 10 mM potassium dihydro-gen phosphate and 2 mM hexane-1-sulfonic 
acid sodium salt (pH adjusted to 5.50 with diluted phosphoric acid) and acetonitrile as 
organic solvent in a gradient program. The flow rate was 0.2 mL min−1 and the 
detection wavelength was 210 nm. The limit of detection (LOD) for Sitagliptin 
phosphate monohydrate and Metformin hydrochloride was 0.2 and 0.06 μg mL−1, 
respectively. The limit of quantification (LOQ) for Sitagliptin phosphate monohydrate 
and Metformin hydrochloride was 0.7 and 0.2 μg mL−1, respectively.  
22. Ghazala Khan35 et.al (2011) developed a simple, precise and highly selective 
analytical method for simultaneous estimation of Metformin HCl and Sitagliptin in 
tablet formulation. Estimation was carried out by multi-component mode of analysis at 
selected wavelength of 232 nm and 267 nm for Metformin HCl and Sitagliptin 
respectively in distilled water. The method was found to be linear in the range of 1-40 
μg/ml and accuracy of the method was confirmed by recovery studies of tablet dosages 
forms and was found to be 99.35% and 98.33% for Metformin HCl and Sitagliptin 
respectively. Initially lab samples were utilized to validate developed method according 
to ICH guidelines followed by determination of % concentration of Metformin HCl and 
Sitagliptin in marketed formulation that was found to be 98.26% ± 0.29 and 97.35% ± 
1.38 respectively.  
23. Sheetal Sharma36 et.al (2012) developed two methods are for the determination of 
Sitagliptin Phosphate and Simvastatin in binary mixture. The first method was based on 
spectrophotometric determination of two, using simultaneous equation method. It 
involves absorbance measurement at 267.0 nm (λmax Sitagliptin Phosphate) and 238.0 
nm (λmax Simvastatin) in methanol: water in a ratio of 90:10(v/v); linearity was 
obtained in the range 10-50 μg/ml and 5 –25μg/ml for both the drugs respectively. The 
second method was based on separation of the two in reverse phase mode using 
Cosmosil C18 column and The mobile phase consisted Ammonium dihydrogen 
orthophosphate: ACN (Ph3 with OPA) in the ratio 50:50v/v that was set at a flow rate 
of1.0ml/min. Linearity was obtained in the concentration range 50-250μg/ml for 
Sitagliptin and 10-50 μg/ml for Simvastatin. Both these methods were validated 
according to ICH guidelines and can be successively applied to pharmaceutical 
formulation. 
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                                             Aim & plan of work 
 Aim and plan of work 
Aim of work 
 
The combination dosage form selected for the present study contains Simvastatin and 
Sitagliptin in solid oral dosage forms, recently this combination has been approved by 
USFDA ( united states food drug administration) in the year 2011. 
The aim of work is to develop and validate a simple, precise, accurate and economical RP-
HPLC method as per ICH guidelines for the estimation of Simvastatin and Sitagliptin in bulk 
and pharmaceutical dosage forms. 
PLAN OF WORK 
 To develop a new RP-HPLC method for the simultaneous estimation of Simvastatin 
and Sitagliptin. 
 To validate the developed method by determining the validation parameters.  
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                 Materials & methods 
Materials and methods 
 
1. Reagents and Standard –  
                                                    Sitagliptin & Simvastatin Tablets were selected with 
a label of sitagliptin 100mg and simvastatin 20mg manufactured by Merck  
                                     a.   Water HPLC Grade.  
                                                 b.   Sitagliptin & Simvastatin Working Standards 
                                                c.   Methanol HPLC Grade 
                                                 d.   Acetonitrite  Hplc grade . 
e. High performance liquid chromatography  
equipped with auto sampler and PDA detector. 
2. Chromatographic Parameters 
Column           -  Agilent C8 (4.6 x 150mm, 3.5m) or equivalent 
 Flow rate         -  0.8 mL per min 
Wavelength           -  254 nm 
Injection volume          - 20 l 
Column oven           -  Ambient 
Run time           -  8.0min. 
 pH                           -  6.26. 
Preparation of Phosphate buffer 
                                          Weighed 2.950 grams of potassium dihydrogen phosphate and 
540mg of dipotassium hydrogen ortho phosphate into a 1000ml beaker, dissolved and diluted 
to 1000ml with HPLC water, the pH was found to be 6.26. 
Preparation of mobile phase 
                                          Mixed the above buffer 250 mL (25%) and 750 mL of Acetonitrile 
HPLC (75%) and degassed in ultrasonic water bath for 5 minutes. Filtered through 0.45 µ 
under vacuum filtration. 
Diluent preparation 
                                    Mixed the above buffer 250 mL (25%) and 750 mL of Acetonitrile 
HPLC (75%) and degassed in ultrasonic water bath for 5 minutes. Filtered through 0.45 µ 
under vacum filtration. 
Standard Solution Preparation 
                                   Accurately weighed and transferred 10 mg each of Sitagliptin & 
Simvastatin working standard into a 10mL clean dry volumetric flask added about 7mL of 
Diluent and sonicated to dissolve it completely and made volume up to the mark with the 
same solvent (Stock solution).Further pipetted 1ml of Sitagliptin & 0.2ml of Simvastatin the 
above stock solution into a 10ml volumetric flask and diluted up to the mark with diluents. 
Sample Solution Preparation 
                                 Accurately weighed and transferred equivalent to 10 mg of Sitagliptin/ 
Simvastatin sample into a 10mL clean dry volumetric flask added about 7mL of Diluent and 
sonicated to dissolve it completely and made volume up to the mark with the same solvent 
(Stock solution). Further pipetted 1.0ml of Sitagliptin & 0.2ml of Simvastatin of the above 
stock solution into a 10ml volumetric flask and diluted up to the mark with Diluent.          
TRAIL-1 
Preparation of mobile phase 
 
The mobile phase was prepared by mixing 0.1M ammonium acetate buffer and Acetonitrile 
in the ratio 20:80. The mobile phase is then sonicated using Ultra-Sonicator to remove the 
impurities and dissolved gases, as they may lead to unwanted peaks in the chromatogram. 
Mobile phase: 0.1M Ammonium acetate buffer: Acetonitrile (20:80) 
Chromatographic Parameters 
Equipment  :       HPLC Shimadzu Separation Module LC-20AT 
Prominence Liquid Chromatograph 
 Column               :         Hypersil BDS 250×4.6, 5µm column 
 Flow rate    :  1.0ml/min 
 Wavelength    :  254nm 
 Injection volume    :  20 µl 
 Column oven    :  Ambient 
 Run time     :  9min 
 
Preparation of mobile phase 
The mobile phase was prepared by mixing 0.1M ammonium acetate buffer and Acetonitrile 
in the ratio 35:65. The mobile phase is then sonicated using Ultra-Sonicator to remove the 
impurities and dissolved gases, as they may lead to unwanted peaks in the chromatogram. 
 
                                         
 
Chromatogram-1 
Conclusion 
The peak shapes are not clear and the retention time of simvastatin was also very low. 
 
TRAIL-2 
Preparation of Mobile phase 
The mobile phase is prepared by mixing sodium acetate buffer (pH-3) and methanol in the 
ratio of 45:55. The mobile phase is then sonicated using Ultra-Sonicator to remove the 
impurities and dissolved gases, as they may lead to unwanted peaks in the chromatogram. 
. 
Mobile phase:   Sodium acetate buffer: methanol (45:55) 
Chromatographic Parameters 
Equipment  :  High performance liquid chromatography equipped with Auto  
Sampler and DAD or   UV detector 
Column   :  Xterra 4.6×150 mm column 
Flow rate   :  1.0ml/min 
Wavelength   :  254nm 
Injection volume  :  20 µl 
Column oven   :  Ambient 
Run time   :  6min 
                                                                     Trail-2 
 
                                                           Chromatogram-2 
Conclusion 
The retention time was very low for simvastatin which has been tried for many 
concentrations.                                                                                     
TRAIL-3 
Preparation of Phosphate buffer 
                                          Weighed 2.950 grams of potassium dihydrogen phosphate and 
540mg of dipotassium hydrogen ortho phosphate into a 1000ml beaker, dissolved and diluted 
to 1000ml with HPLC water, the pH was found to be 6.26. 
The mobile phase is prepared by mixing Phosphate  buffer (pH-6.26) and Acetonitrile in the 
ratio of 50:50. The mobile phase is then sonicated using Ultra-Sonicator to remove the 
impurities and dissolved gases, as they may lead to unwanted peaks in the chromatogram. 
Mobile phase:   Phosphate buffer: methanol (50:50) 
Chromatographic Parameters 
Equipment  :  High performance liquid chromatography equipped with Auto  
Sampler and DAD or   UV detector 
Column   :  Xterra 4.6×150 mm column 
Flow rate   :  1.0ml/min 
Wavelength   :  254nm 
Injection volume  :  20 µl 
Column oven   :  Ambient. 
Run time   :  6min 
 
Chromatogram-3 
Conclusion 
The usp plate count was found to be less and the retention time was found to be less for 
sitagliptin with an less tailing which was found unsatisfactory.  
 
TRAIL-4 
Preparation of Phosphate buffer 
                                          Weighed 2.950 grams of potassium dihydrogen phosphate and 
540mg of dipotassium hydrogen ortho phosphate into a 1000ml beaker, dissolved and diluted 
to 1000ml with HPLC water, the pH was found to be 6.26. 
The mobile phase is prepared by mixing Phosphate  buffer (pH-6.26) and Acetonitrile in the 
ratio of 40:60. The mobile phase is then sonicated using Ultra-Sonicator to remove the 
impurities and dissolved gases, as they may lead to unwanted peaks in the chromatogram. 
Mobile phase:   Phosphate buffer: methanol (40:60) 
Chromatographic Parameters 
Equipment  :  High performance liquid chromatography equipped with Auto  
Sampler and DAD or   UV detector 
Column   :  BDS 4.6×250 mm column 
Flow rate   :  0.9ml/min 
Wavelength   :  254nm 
Injection volume  :  20 µl 
Column oven   :  Ambient 
Run time   :  6min 
 
 
Chromatogram-4 
Conclusion 
The small hump was seen in chromatogram with less tailing and plate count which was 
carried for many times hence found unsatisfactory. 
 
TRAIL-5 
Preparation of Phosphate buffer 
                                          Weighed 2.950 grams of potassium dihydrogen phosphate and 
540mg of dipotassium hydrogen ortho phosphate into a 1000ml beaker, dissolved and diluted 
to 1000ml with HPLC water, the pH was found to be 6.26. 
The mobile phase is prepared by mixing Phosphate  buffer (pH-6.26) and Acetonitrile in the 
ratio of 30:70. The mobile phase is then sonicated using Ultra-Sonicator to remove the 
impurities and dissolved gases, as they may lead to unwanted peaks in the chromatogram. 
Mobile phase:   Phosphate buffer: methanol (30:70) 
Chromatographic Parameters 
Equipment  :  High performance liquid chromatography equipped with Auto  
Sampler and DAD or   UV detector 
Column   :  Waters 5.6×150 mm column 
Flow rate   :  1.0ml/min 
Wavelength   :  254nm 
Injection volume  :  20 µl 
Column oven   :  Ambient 
Run time   :  6min 
 
Chromatogram-5 
Conclusion 
The peak shape was not clear for simvastatin resolution was found to be less with less plate 
count hence tried by changing the concentration which gave rise to the optimized method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OPTIMISED METHOD  
                                            The objective of this experiment was to optimize the assay 
method for estimation of Simvastatin and Sitagliptin based on the literature survey .So here 
the trials mentioned describes how the optimization was done. 
Preparation of buffer 
                          Mixture of above buffer 250 ml (25%) and 750 mL of Acetonitrile HPLC 
(75%) are mixed and degassed in ultrasonic water bath for 5 minutes. Filtered through 0.45 µ  
under vacuum filtration. The mobile phase is sonicated using Ultra-Sonicator for 5min to 
remove the impurities and dissolved gases, as they may lead to unwanted peaks in the 
chromatogram. 
 
Mobile phase:  Mixed phosphate buffer: Acetonitrile (25:75). 
 
Chromatographic Parameters 
           
Equipment: High performance liquid chromatography equipped with Auto Sampler 
and DAD or UV detector 
            Column                        -        Agilent C8 (4.6 x 150mm, 3.5m) or equivalent 
            Flow rate  -       0.8 ml per min 
Wavelength  -  254 nm 
 Injection volume -  20 l 
 Column oven   -  Ambient 
 Run time   -  8.0min 
            PH                                - 6.26. 
 
  
 
 
METHOD DEVELOPMENT 
CHROMATOGRAM-6 
Conclusion 
                                                         The retention time, shape, resolution were found to be 
good when compared to other methods in trails, hence this method was finalized for the 
estimation of Simvastatin and Sitagliptin. A simple and sensitive reverse phase HPLC 
method has been developed for simultaneous analysis of Simvastatin and Sitagliptin in 
combined dosage form. The method utilizes sample preparation followed by separation on a 
Agilent C8 (4.6 x 150mm, 3.5m). 
Analytes were monitored by UV detection at 254nm using an isocratic mode with Mixed 
phosphate buffer (ph-6.26): Acetonitrile in the ratio 25:75 as mobile phase. The flow rate was 
set at 0.8 ml/min and effluent was monitored at 254nm. The retention time was 2.475min and 
6.528min for Simvastatin and Sitagliptin respectively. 
METHOD VALIDATION      
System suitability 
Preparation of Phosphate buffer 
                                          Weighed 2.950 grams of potassium dihydrogen phosphate and 
540mg of dipotassium hydrogen ortho phosphate into a 1000ml beaker, dissolved and diluted 
to 1000ml with HPLC water and the PH was found to be 6.26. 
Preparation of mobile phase 
                                         Mixture of above buffer 250 ml (25%) and 750 ml of Acetonitrile 
HPLC (75%) are mixed and degassed in ultrasonic water bath for 5 minutes. Filtered through 
0.45 µ filtered under vacuum filtration. 
Diluent preparation 
                                 Mixture of above buffer 250 ml (25%) and 750 ml of Acetonitrile 
HPLC grade (75%) are mixed and degassed in ultrasonic water bath for 5 minutes. Filtered 
through 0.45 µ filtered under vacuum filtration. 
Standard solution Preparation 
                                  Accurately weighed and transferred 10 mg each of Sitagliptin & 
Simvastatin working standard into a 10ml clean dry volumetric flask added about 7ml of 
Diluent and sonicated to dissolve it completely and made volume up to the mark with the 
same solvent. (Stock solution).Further pipetted 1ml of Sitagliptin & 0.2ml of Simvastatin the 
above stock solution into a 10ml volumetric flask and diluted up to the mark with diluents. 
Sample Solution Preparation 
                                Accurately weighed and transferred equivalent to 10 mg of Sitagliptin& 
10mg of Simvastatin sample into a 10ml clean dry volumetric flask added about 7ml of 
Diluent and sonicated it for 5min to dissolve it completely and made volume up to the mark 
with the same solvent. (Stock solution). Further pipetted 1.0ml of Sitagliptin & 0.2ml of 
Simvastatin of the above stock solution into a 10ml volumetric flask and diluted up to the 
mark with Diluent.          
    System suitability parameters are integral part of liquid chromatographic methods. They 
are used to verify that the resolution and reproducibility of the chromatographic system are 
adequate for the analysis to be done. The key to achieving system suitability is an optimal 
instrumentation and an efficient analytical column. System suitability test is a 
pharmacopoeial requirement. A few commonly used system suitability parameters are given 
below. 
Theoretical plates (N) 
 
                                 It is measure of column efficiency. A column can be considered as being 
made of large number of theoretical plates where distribution of sample between liquid - 
liquid or solid - liquid phase occurs. The number of theoretical plates in column is given by 
the relationship. 
                                               N = 16 (tR/W)2 
                                                      (OR) 
                                               N = 5.54 (tR/W1/2)2 ----- (1) 
Where, 
tR = Retention time 
W = width at the base of the peak. 
N should be > 2000. 
 
Retention time (Rt) 
                                Retention time is the time required for elution of the peak maximum after 
injection of compound. 
 
Resolution (Rs) 
                                 It is a function of column efficiency and is specified to ensure that 
closely eluting compounds are resolved from each other to establish the general resolving 
power of the system. For the separation of two components in mixture, the resolution is 
determined by equation. 
                                      Rs = 2 (tR2 – t R1) / (W1+W2) ----- (2) 
Where, 
d t1 = Retention times of second and first compounds respectively 
W2 and W1 = Corresponding widths at the bases of peak obtained by 
extrapolating straight sides of the peaks to baselines. 
Tailing factor (T) 
                                     It is the measure of peak symmetry and is unity for perfectly 
symmetrical peaks and its value increases as tailing becomes more pronounced. 
                                           T = W 0.05 / 2 f ----- (3) 
Where,    W0.05 =width of peak at 5 % height 
f = distance from the peak maximum to the leading edge of the peak height from the baseline. 
 
System suitability-1   
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Data of system suitability for Sitagliptin and Simvastatin 
       
Serial 
number 
Parameter Sitagliptin Simvastatin Acceptance criteria 
 
1 
 
 
Theoretical 
plates 
 
2286.158 
 
4608.944 
 
Theoretical plate count 
should be more than 2000. 
 
2 
 
 
Retention 
time 
 
2.232 
 
5.6754 
 
Retention time should be 
more than 2. 
 
3 
 
 
Resolution 
 
11.27 
 
11.27 
 
Resolution between two 
peaks must be more than 2 
 
4 
 
 
Tailing factor 
 
1.264 
 
1.316 
 
Tailing factor must be less 
than 2. 
                                                        Table-3 
  
 
 
 
 
 
 
 
 
 
 
 
SPECIFICITY 
Standard Solution Preparation 
                                                 Accurately weighed and transferred 10 mg each of Sitagliptin 
& Simvastatin working standard into a 10mL clean dry volumetric flask added about 7mL of 
diluent and sonicated to dissolve it completely and made volume up to the mark with the 
same solvent. (Stock solution) 
Further pipetted 1ml of Sitagliptin & 0.2ml of Simvastatin the above stock solution into a 
10ml volumetric flask and diluted up to the mark with diluents. 
Sample Solution Preparation 
                                                 Accurately weighed and transferred equivalent to 10 mg of 
Sitagliptin / Simvastatin sample into a 10mL clean dry volumetric flask added about 7mL of 
diluent and sonicated to dissolve it completely and made volume up to the mark with the 
same solvent. (Stock solution). 
Further pipetted 1.0ml of Sitagliptin & 0.2ml of Simvastatin of the above stock solution into 
a 10ml volumetric flask and diluted up to the mark with diluent. 
Preparation of Placebo solution 
                                                     Accurately weighed a quantity of placebo powder 87.6mg of 
placebo in a 50ml volumetric flask added 30ml of diluent and made upto volume with 
diluent. Filtered using 0.45 micron membrane filtered. Diluted 5ml to 10ml with diluent. 
Preparation of Placebo+ Standard solution 
                                                      Diluted 5ml of the standard stock solution into 10ml 
volumetric flask made up the volume with the placebo solution. 
 
Acceptance criteria 
                                               There should not be any interference due to placebo in sample 
and standard preparation. 
                                           
 
                SPECIFICITY-BLANK 
 
Serial 
number 
Retention time Peak   area Tailing factor Number of 
theoretical 
plates 
                                                    NO PEAKS WERE FOUND 
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SPECIFICITY-PLACEBO 
 
 
 
Serial 
number 
 
Retention time 
 
Peak   area 
 
Tailing factor 
Number 
of 
theoretical 
plates 
                                            NO PEAKS WERE FOUND 
                                            Chromatogram-13 
                                        
                            
SPECIFICITY-SITAGLIPTIN STANDARD 
 
                                              Chromatogram-14 
                             
 
 
 
SPECIFICITY- SIMVASTATIN STANDARD 
 
                                                Chromatogram-15 
                              
 
 
 
SPECIFICITY-MIXED STANDARD 
                             
 
                                                Chromatogram-16                 
 
 
                                
 
 
 
SPECIFICITY-PLACEBO+STANDARD 
 
                                                               Chromatogram-17 
 
 
                                
 
 
SPECIFICITY-SAMPLE SOLUTION 
 
                                                        Chromatogram-18 
 
 
 
                                                Chromatogram-19&20 
 
                                                 Chromatogram 21&22 
     
  
 
LINEARITY 
Preparation of stock solution  
                                                  Accurately weighed and transferred 10 mg of Sitagliptin and 
Simvastatin working standard into a 10mL clean dry volumetric flask added about 7mL of 
Diluent and sonicated to dissolve it completely and made volume up to the mark with the 
same solvent. (Stock solution) 
Preparation of Level – I (80ppm of Sitagliptin & 16ppm of Simvastatin) 
                     0.8ml of stock solution has taken in 10ml of volumetric flask diluted up to the 
mark wit diluent.  
Preparation of Level – II (90ppm of Sitagliptin & 18ppm of Simvastatin) 
                     0.9ml of stock solution has taken in 10ml of volumetric flask diluted up to the 
mark with diluent.  
Preparation of Level – III (100ppm of Sitagliptin & 20ppm of Simvastatin) 
                   1.0ml of stock solution has taken in 10ml of volumetric flask diluted up to the 
mark with diluent.  
Preparation of Level – IV (110ppm of Sitagliptin & 22ppm of Simvastatin) 
                   1.1ml of stock solution has taken in 10ml of volumetric flask diluted up to the 
mark with diluent.  
Preparation of Level – V (120ppm of Sitagliptin & 24ppm of Simvastatin) 
                   1.2ml of stock solution has taken in 10ml of volumetric flask diluted up to the 
mark with diluent. 
Procedure 
Inject each level into the chromatographic system and measure the peak area. 
Plot a graph of peak area versus concentration (on X-axis concentration and on Y-axis Peak 
area) and calculate the correlation coefficient. 
Acceptance criteria 
The Linear Regression coefficient should not be less than 0.995. 
 
 
LINEARITY 
 
                                                                      Chromatogram-23 
                                                         Chromatogram-24&25 
                                                      Chromatogram-26&27 
 
 
  Linearity Results (for Sitagliptin) 
 
                                                                            Table-4 
     Acceptance Criteria 
 Correlation coefficient should be not less than 0.999. 
 
 
Sr.no Concentration Area    Average area 
1 80ppm 
2115841  
  2115842 2115843 
2115844 
2 90ppm 
2360794  
    2360795 
 
2360796 
2360797 
3 100ppm 
2567566   
   2567567 2567568 
2567569 
4 110ppm 
2780461  
   2780462 2780463 
2780464 
5 120ppm 
2986885  
   2986886 2986887 
2986888 
 
Correlation coefficient 0.999 
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Linearity Results: (for Simvastatin) 
 
S.No Concentration Area Average area 
1 16ppm 
1028432  
1028433 1028434 
1028435 
2 18ppm 
1117783  
1117784 1117785 
1117786 
3 20ppm 
1205381  
1205382 1205383 
1205384 
4 22ppm 
1301560  
1301561 1301562 
1301563 
5         24ppm 
1403960  
1403961 1403962 
1403963 
Correlation coefficient 0.999 
                                                                 Table-5 
Acceptance Criteria 
Correlation coefficient should be not less than 0.999. 
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ASSAY 
 
Standard drug solution 
                                   The standard stock solution was further diluted appropriately in mobile 
phase to get final concentration of 100mg/ml of Sitagliptin and 20mg/ml of Simvastatin. 
Sample Stock solution 
                                                   Twenty tablets were weighed and finely powdered. 
Accurately weighed and transferred a quantity of tablet powder equivalent to 100mg of 
Sitagliptin and 20mg of Simvastatin working sample into a 100ml clean dry volumetric flask 
containing mobile phase. The solution was sonicated for about 10mins and then made upto 
volume with mobile phase and filtered. Diluted 10ml of the above solution to 100ml with 
mobile phase. 
Preparation of Sample solution 
                                               Diluted 5ml from the above solution to 10ml with the mobile 
phase in a 10ml volumetric flask. 
Procedure 
                                             The chromatographic conditions were set as detailed under the 
study of linearity range and mobile phase was allowed to equilibrate with stationary phase. 
Equal volumes of standard and sample solution were injected separately. The chromatograms 
were recorded. The contents of Simvastatin and Sitagliptin were calculated 
 
Assay % =  
                                    
       AT       WS             DT         P             Avg. Wt 
 -------------- x ----------x --------- x ----------x------------------ X 100 
      AS           DS          WT         100       Label Claim 
  
Where  
AT = average area counts of sample preparation. 
As= average area counts of standard preparation. 
WS = Weighed of working standard taken in mg. 
P     = Percentage purity of working standard. 
LC =     Label claim Sitagliptin mg/ml.              
 
Assay Results (Sitagliptin) 
  
 2556801     10         1        10           10         99.8                568                                
---------- x -------x ------ x --------- x-------x --------- x100 x ---------   =99.67% 
2596712     10         10         56           1          100                   100 
 
Calculation (For Simvastatin) 
Assay % =                            
       AT       WS             DT         P             Avg. Wt 
 -------------- x ----------x --------- x ----------x------------------ X 100 
      AS           DS          WT         100       Label Claim 
Where  
AT = average area counts of sample preparation. 
As= average area counts of standard preparation. 
WS = Weighed of working standard taken in mg. 
P     = Percentage purity of working standard  
LC =     Label claim of Simvastatin mg/ml.              
 Assay results   
             1234163           10          0.2         10           10            99.7                  568 
        --------------- x ----------x --------- x --------- x --------x --------- x 100 x   -------   =99.42% 
            1237668            10           10          284        0.2           100                    20     
 
 
 
 
                                                        ASSAY-SAMPLE 
 
Chromatogram-28 
 
                                                          
 
                                                        
 
ASSAY STANDARD 
 
                                                            Chromatogram-29 
 
 
 
 
 
 
Accuracy 
Preparation of Standard stock solution  
                                   Accurately weighed and transferred 20 mg of Sitagliptin and 
Simvastatin working standard into a 10mL clean dry volumetric flask added about 7mL of 
Diluent and sonicated to dissolve it completely and made volume up to the mark with the 
same solvent. (Stock solution. 
Further pipetted 1.0ml of Sitagliptin & 0.2ml of Simvastatin of the above stock solution into 
a 10ml volumetric flask and diluted up to the mark with diluent. 
 Preparation Sample solutions 
For preparation of 50% solution (With respect to target Assay concentration) 
    Accurately weighed and transferred 10.0mg equivalent of Sitagliptin 
and Simvastatin into a 10mL clean dry volumetric flask added about 7mL of Diluent and 
sonicated to dissolve it completely and made volume up to the mark with the same solvent. 
(Stock Solution) 
Further pipetted 1.0ml of Sitagliptin & 0.2ml of Simvastatin of the above stock solution into 
a 10ml volumetric flask and diluted up to the mark with diluent. 
For preparation of 100% solution (With respect to target Assay concentration) 
                             Accurately weighed and transferred 20mg of Sitagliptin and 
Simvastatin working standards into a 10mL clean dry volumetric flask added about 7mL of 
Diluent and sonicated to dissolve it completely and made volume up to the mark with the 
same solvent. (Stock solution) 
Further pipetted 1.0ml of Sitagliptin & 0.2ml of Simvastatin of the above stock solution into 
a 10ml volumetric flask and diluted up to the mark with diluent. 
For preparation of 150% solution (With respect to target Assay concentration) 
Accurately weighed and transferred 30mg of Sitagliptin and Simvastatin working standards 
into a 10mL clean dry volumetric flask added about 7mL of Diluent and sonicated to dissolve 
it completely and made volume up to the mark with the same solvent. (Stock solution) 
Further pipetted 1.0ml of Sitagliptin & 0.2ml of Simvastatin of the above stock solution into 
a 10ml volumetric flask and diluted up to the mark with diluent. 
Procedure 
Injected the standard solution, Accuracy -50%, Accuracy -100% and Accuracy -150% solutions.  
      Calculated the Amount found and Amount added for Sitagliptin & Simvastatin and calculated 
the individual recovery and mean recovery values. 
ACCURACY-STANDARD-1 
Chromatogram-30 
                                               ACCURACY-STANDARD-2 
 
 Chromatogram-31 
                                               
 
                                         
 
 
ACCURACY-50% 
 
                                                  Chromatogram-32 
  
  
 
                                             Chromatogram-33&34 
 
                                                  
ACCURACY-100% 
 
                                                           Chromatogram-35 
 
                                          Chromatogram-36&37 
 
ACCURACY-150% 
 
                                            Chromatogram-38 
 
                                                         Chromatogram-39&40 
 
 
 
 
 
The accuracy results for Sitagliptin 
%Concentration 
(at specification 
Level) 
Area 
Amount 
Added 
(mg) 
Amount 
Found 
(mg) 
% Recovery Mean Recovery 
50% 2639988 10.0 10.21      102.14% 
100.22% 100% 5160066        20.0 19.96 99.82% 
150% 7653938       30.0 29.61 98.71% 
                        Table-6 
Acceptance Criteria 
The % Recovery for each level should be between 98.0 to 102.0%. 
 
The accuracy results for Simvastatin  
%Concentration 
(at specification 
Level) 
Area 
Amount 
Added 
(mg) 
Amount 
Found 
(mg) 
% Recovery Mean Recovery 
50% 1239691 10.4 10.47 100.69% 
100.54% 100% 2359402 20.0      19.93     99.65%                
150% 3357441 28.0 28.36 101.29% 
                                      Table-7 
    Acceptance Criteria 
   The % Recovery for each level should be between 98.0 to 102.0%. 
 
 
System Precision 
 Preparation of stock solution 
                                             Accurately weighed and transferred 10 mg of Sitagliptin and 
Simvastatin working standard into a 10mL clean dry volumetric flask added about 7mL of 
Diluent and sonicated to dissolve it completely and made volume up to the mark with the same 
solvent. (Stock solution). 
                                             Further pipetted 1ml of Sitagliptin & 0.2ml of Simvastatin of the 
above stock solution into a 10ml volumetric flask and diluted up to the mark with diluent.  
Procedure 
                                               The standard solution was injected for five times and measured the area 
for all five injections in HPLC. The %RSD for the area of five replicate injections was found to be 
within the specified limits. 
SYSTEM PRECISION 
 
                                                               Chromatogram-41 
    
                                                         Chromatogram-42&43 
  
                                                         Chromatogram-44&45 
 
 
 
 The results are summarized for Sitagliptin and Simvastatin 
Sr.no        Sitagliptin        Simvastatin 
1 2600572 1240270 
2 2624671 1245251 
3 2617396 1247103 
4 2610977 1245022 
5 2619579 1245921 
Average 2614639 1244713 
       Standard Deviation 9272.7 2612.3 
%RSD 0.35 0.21 
                                                               Table-8 
 Acceptance Criteria 
                    The % RSD for the area of five standard injections results should not be more 
than 2%. 
                                                      
 
 
 
 
 
 
 
 
 
 
Method Precision 
                Six sample preparations of the Simvastatin and Sitagliptin tablets shall be prepared 
and analyzed as per the method. 
Preparation of Sample Stock Solution 
                                  Accurately weighed and transferred the powder of sample equivalent to 
100mgof Sitagliptin and 20mg separately six times into a different 50ml clean dry volumetric 
flask and added mobile phase. The solutions was sonicated for about 10mins and then made 
upto volume with mobile phase. Diluted 5ml of the above solution to 50ml with mobile 
phase. 
Preparation of sample solution 
                                  Diluted 5ml from the above solutions to 10ml with the mobile phase in a 
10ml volumetric flask.( 100mgSitagliptin&20 mg of Simvastatin).  
 
Procedure 
               The standard solution was injected for five times and measured the area for all five 
injections in HPLC. The %RSD for the area of five replicate injections was found to be within the 
specified limits. 
METHOD PRECISION 
 
                                                    Chromatogram-46 
 
                                                    Chromatogram-47&48 
 
                                               Chromatogram-49&50 
 
 
 
 
The results are summarized for  Sitagliptin and Simvastatin 
Sr.no Sitagliptin Area Simvastatin area 
1 2600572 1225584 
2 2607709 1231724 
3 2599166 1228089 
4 2601972 1223118 
5 2609884 1226449 
Average 2603861 1226993 
Standard Deviation 4677.3 3196.9 
%RSD 0.18 0.26 
                                                                                Table-9 
Acceptance Criteria 
        The % RSD for the area of five standard injections results  should  not be more than  2%.                                   
                
 
 
 
 
 
 
 
 
 
 
 
Sensitivity 
    The Sensitivity of measurement of Simvastatin and Sitagliptin by use 
of the proposed method was estimated in terms of the limit of detection (LOD) and the Limit 
of Quantitation (LOQ). The LOD and LOQ were calculated by the use of the equations LOD 
= 3.3 × σ / S and LOQ = 10 × σ / S where σ is the standard deviation of intercept of 
Calibration plot and S is the average of the slope of the corresponding Calibration plot.  
Limit of quantification (For Sitagliptin) 
Preparation of 100µg/ml solution   
                                     Accurately weighed and transferred 10mg of Sitagliptin sample into a 
10mL clean dry volumetric flask added about 7mL of Diluent and sonicated to dissolve it 
completely and made volume up to the mark with the same solvent. (Stock solution) 
Further pipetted 1ml of the above stock solution into a 10ml volumetric flask and diluted up 
to the mark with diluent. 
Preparation of 0.4% solution At Specification level (0.4µg/ml solution) 
                                  Further pipetted 1ml of the above stock solution into a 10ml volumetric 
flask and diluted up to the mark with diluent. 
Pipetted 0.4mL of 10µg/ml solution into a 10 ml of volumetric flask and diluted up to the 
mark with diluent. 
Limit of quantification (For Simvastatin) 
Preparation of 20µg/ml solution 
                                     Accurately weighed and transferred 10mg of Simvastatin sample into 
a 10mL clean dry volumetric flask added about 7mL of Diluent and sonicated to dissolve it 
completely and made volume up to the mark with the same solvent. (Stock solution) 
Further pipetted 0.2ml of the above stock solution into a 10ml volumetric flask and diluted up 
to the mark with diluent. 
Preparation of 1.2% solution at Specification level (0.24µg/ml solution) 
                                 Further pipetted 1ml of the above stock solution into a 10ml volumetric 
flask and diluted up to the mark with diluent. 
Pipetted 1.2mL of 2µg/ml solution into a 10 ml of volumetric flask and diluted up to the mark 
with diluent. 
LIMIT OF QUANTIZATION 
 
                                                    Chromatogram-51 
 
Calculation of S/N Ratio for Sitagliptin 
Average Baseline Noise obtained from Blank        :   95 µV 
Signal Obtained from LOQ solution (0.4% of target assay concentration) :    945µV 
S/N =        945/95 = 9.95. 
Acceptance Criteria 
S/N Ratio value shall be 10 for LOQ solution. 
Calculation of S/N Ratio for Simvastatin 
 Average Baseline Noise obtained from Blank         :    95 µV 
Signal Obtained from LOQ solution (1.2% of target assay concentration) :    951µV 
S/N =        951/95 = 10.01. 
 Acceptance Criteria 
                            S/N Ratio value shall be 10 for LOQ solution. 
 
Limit of detection (for Sitagliptin)  
Preparation of 100µg/ml solution 
                                               Accurately weighed and transferred 10mg of Sitagliptin 
working standard into a 10mL clean dry volumetric flask added about 7mL of Diluent and 
sonicated to dissolve it completely and made volume up to the mark with the same solvent. 
(Stock solution) 
                                               Further pipetted 1ml of the above stock solution into a 10ml 
volumetric flask and diluted up to the mark with diluent. 
Preparation of 0.13% solution At Specification level (0.13µg/ml solution) 
                                             Further pipetted 1ml of the above stock solution into a 10ml 
volumetric flask and diluted up to the mark with diluent. 
                                             Pipetted 0.13mL of 10µg/ml solution into a 10 ml of volumetric 
flask and diluted up to the mark with diluent. 
Limit of detection (for Simvastatin) 
Preparation of 20µg/ml solution  
                                         Accurately weighed and transferred 10mg of Simvastatin Sample 
into a 10mL clean dry volumetric flask added about 7mL of Diluent and sonicated to dissolve 
it completely and made volume up to the mark with the same solvent. (Stock solution). 
Further pipetted 0.2ml of the above stock solution into a 10ml volumetric flask and diluted up 
to the mark with diluent. 
Preparation of 0.35% solution At Specification level (0.07µg/ml solution) 
                                        Further pipetted 1ml of the above stock solution into a 10ml 
volumetric flask and diluted up to the mark with diluent. 
                                                Pipetted 0.35mL of 2µg/ml solution into a 10 ml of volumetric 
flask and diluted up to the mark with diluent.                     
BLANK FOR LOD & LOQ 
Chromatogram-52
LIMIT OF DETCTION 
 
                                                    Chromatogram-53 
 
 
 
 
Calculation of S/N ratio for Sitagliptin 
Average Baseline Noise obtained from Blank   :    95 µV 
Signal Obtained from LOD solution (0.13% of target assay concentration) :    285 µV 
S/N =        285/95 =   3.00  
Acceptance Criteria 
S/N Ratio value shall be 3 for LOD solution. 
Calculation of S/N ratio Simvastatin 
Average Baseline Noise obtained from Blank   :    95 µV 
Signal Obtained from LOD solution (0.35% of target assay concentration) :    298 µV 
S/N =        298/95 =   3.14 
Acceptance criteria 
S/N Ratio value shall be 3 for LOD solution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Robustness 
 
                                  As part of the Robustness, deliberate change in the Flow rate, 
Mobile Phase composition, Temperature Variation was made to evaluate the impact on 
the method. 
a. The flow rate was varied at 0.7 ml/min to 0.9ml/min. 
                                      Standard solution 100ppm of Sitagliptin & 20ppm of Simvastatin 
was prepared and analysed using the varied flow rates along with method flow rate.  
                                           
ROBUSTNESS 
   
                                                                  Chromatogram-54 
                                         
 
                                                 
ROBUSTNESS 
 
                                                           Chromatogram-55 
The results are summarized  
On evaluation of the above results, it can be concluded that the variation in flow rate does 
not affect the method significantly. Hence it indicates that the method is robust even by 
change in the flow rate ±0.1%. 
 b.  The Organic composition in the Mobile phase was varied from 70% to 80%. 
                         standard solution 100 µg/ml of Sitagliptin & 20ppm of Simvastatin was prepared 
and analysed using the varied Mobile phase composition along with the actual mobile phase 
composition in the method.  
                      ROBUSTNESS 
 
                                                  Chromatogram-56 
                                                     
 
                                                                          ROBUSTNESS 
    Chromatogram-57 
   The results are summarized  
                                 On evaluation of the above results, it can be concluded that the variation in 5% 
Organic composition in the mobile phase affected the method significantly. Hence it 
indicates that the method is robust even by change in the Mobile phase ±5% 
Robustness results for Sitagliptin    
 Serial number Parameter 
variation 
 Area of 
Sitagliptin 
       % RSD 
            
              1. 
 
Flow 
rate 
 
 
0.7 
    2975037  
0.1165 
 
    2975108 
    2975087 
 
 
 
 
0.1281 
    232619 
 
0.9 
    232605 
    232622 
 
 
              2. 
 
 
Organic 
phase 
 
70 
    2563842  
0.1185 
 
 
 
 
0.1321 
    2563951 
    2563901 
 
 
80 
    2644123 
    2645456 
    2643849 
                                                         
                                                                             Table-10 
Results for actual Mobile phase composition (75:25 Acetonitrile: Buffer) have been 
considered from Assay standard. 
     
 
 
 
 
 
 
Robustness results for Simvastatin 
  Serial 
number 
Parameter 
variation 
 Area of 
Sitagliptin 
       % RSD 
            
              1. 
 
Flow 
rate 
 
0.7 
    1417227  
0.124   
 
 
 
 
0.269 
    1417442 
    1417589 
 
 
 
 
0.9 
     1104266 
      1104236 
      1104671 
 
 
              2. 
 
 
Organic 
phase 
 
 
70 
      1210154  
0.198 
 
 
 
 
 
 
0.312 
      1211123 
      1242810 
 
 
80 
     1229838 
     1230152 
     1231268 
                                                                           Table-11 
 Results for actual Mobile phase composition (75:25 Acetonitrile: Buffer) have been 
considered from Assay standard. 
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                 Results & discussion 
 
 
Results and discussion 
6.1. Results Of Validation 
 
The following validation parameters were performed and the results obtained were observed 
to be in the given ICH limits. 
 
Sr.no 
 
  parameter 
  Acceptance 
        Limit 
                     Observed values 
     Sitagliptin    Simvastatin 
 
   1. 
 
 
System 
suitability 
 
 
%RSD should be 
NMT 2 
 
          %RSD          %RSD 
1.785979443 1.062447522 
 
 
    
     2. 
     
      Linearity 
 
Correlation 
coefficient should 
be not less than 
0.999 
 
      
0.999 
 
    
0.999 
  
    
     3. 
     
      Assay 
 
%Purity- 
(97%-103%) 
 
99.67% 
 
99.42% 
 
    
     4. 
     
      Accuracy 
 
%Recovery range is 
90-110% 
 
      100.22 
 
100.54 
   
 
    
     5. 
     
    System 
precision   
 
%RSD should be 
NMT 2 
 
0.35 
 
0.21 
 
   
  
    
     6. 
     
    Method  
precision   
 
%RSD should be 
NMT 2 
 
0.16 
 
0.25 
 
   
  
    
     7. 
     
    LOD   
  
S/N ratio shall  be 3 
 
3 
 
3.14 
 
   
 
    
     8. 
     
    LOQ   
 
S/N ratio Shall be 
10 
 
9.05 
 
10.01 
 
   
 
    
     
 
 
 9. 
     
   
 
 
  Robustness  
 
 
 
 
% RSD shall not be 
more than 5 
    Flow rate  Wavelength 
Less flow      More 
flow 
Less 
organic 
More 
organic 
0.7-0.1165 0.9-
0.1281 
241-
0.1185 
   
267-
0.1321 
 
0.7-0.124 0.9-
0.269 
241-
0.198 
267-
0.312 
 
                                                                     Table -12 
 
For routine analytical purpose, it is always necessary to establish methods capable of 
analyzing huge number of samples in a short time period with due accuracy and precision. 
 
Sitagliptin and Simvastatin are official in Indian Pharmacopoeia. There is one spectroscopic 
method appeared in the literature for the simultaneous determination of the both drugs 
includes. In literature review we have methods only for the estimation of the above drugs of 
concern by RP-HPLC individually or in combination with others. In view of the above, a 
simple and specific analytical method was planned to develop with sensitivity, accuracy, 
precision and economical. 
 
In the present investigation, RP-HPLC method for the quantitative estimation of Sitagliptin 
and Simvastatin in bulk drug and pharmaceutical formulations has been developed and 
validated. The summary results of all validation parameters were expressed in Table-12. 
 
The proposed RP-HPLC method is more sensitive, accurate, precise and economic and is 
suggested for routine analysis of the both drugs in tablet dosage form. 
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              summary&  conclusion 
 
 
 
Summary and conclusion 
In the present work, an attempt was made to provide a newer, sensitive, simple, accurate and 
low cost RP-HPLC method. It is successfully applied for the determination of Sitagliptin and 
Simvastatin in pharmaceutical preparations without the interferences of other constituent in 
the formulations. 
In this method, HPLC conditions were optimized to obtain, an adequate separation of eluted 
compounds. Initially, various mobile phase compositions were tried, to get good optimum 
results. Mobile phase and flow rate selection was based on peak parameters (height, tailing, 
theoretical plates, run time etc). The system with Mixed Phosphate Buffer: acetonitrile 
(25:75) with 0.8 ml/min flow rate is quite robust. 
The optimum wavelength for detection was 254nm at which better detector response for the 
both drugs were obtained. The average retention time for Simvastatin and Sitagliptin were 
found to be 2.475 and 6.528. 
In specificity it is found that there is no interference of any placebo and blank peaks with the 
drugs of the analysis concern. 
The calibration was linear in concentration range of 80-120 µg/ml for Sitagliptin and 16-24 
µg/ml for Simvastatin respectively. The sensitivity for the both drugs has been calculated and 
the LOD and LOQ of the Sitagliptin was found to be 3.0 µg and 9.95µg and for Simvastatin 
was found to be 3.14µg and 10.01µg. 
The low values of % R.S.D. indicate the method is precise and accurate. The mean recoveries 
were found in the range of 99.67 – 100.27 % for Sitagliptin and 99.42 – 100.54% for 
Simvastatin respectively.Ruggedness of the proposed methods was determined by analysis of 
aliquots from homogeneous slot by different analysts, using similar operational and 
environmental conditions; the % R.S.D. reported was found to be less than 2 %. 
The proposed method was validated in accordance with ICH parameters and the results of all 
methods were very close to each other as well as to the label value of commercial 
pharmaceutical formulation. Therefore, there is no significant difference in the results 
achieved by the proposed method. 
Hence it is suggested that the proposed isocratic RP-HPLC methods can be effectively 
applied for the routine analysis of Simvastatin and Sitagliptin in tablet formulation.
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